resulted in accidents. Some patients perceived no warning signs, such as excessive drowsiness. Hallucinations were reported in 2.0% of patients treated with Neupro® compared to 0.7% of patients on placebo. Neupro® contains metabisulfite. Neupro® should be used with caution in patients, especially those at risk for cardiovascular disease, because of the potential for symptomatic hypotension, syncope, elevated heart rate, elevated blood pressure, fluid retention, and/or weight gain. All Parkinson's disease patients are at a higher risk for melanoma and should be monitored regularly. The most commonly reported side effects in clinical trials were nausea, application site reactions, somnolence, dizziness, headache, vomiting, and insomnia. Some subjects who received Neupro® experienced a decline in blood hemoglobin levels (about 2% relative to subjects who received placebo). It is not known whether this change is readily reversible with discontinuation of Neupro®. Please go to http://www.neupro.com/documents/Neupro_PI_071207.pdf
for US Full Prescribing Information.
Neupro® is a registered trademark of the UCB Group of companies.
About rotigotine transdermal in Canada
Rotigotine transdermal is not authorized for sale in Canada.
For further information
Nancy Nackaerts, External Communications, UCB
T +32.473.864.414, firstname.lastname@example.org
Eimear O'Brien, Associate Director, Global CNS Communications UCB
T +32.2.559.9271, email@example.com
Andrea Levin, Senior Manager, Communications & PR, U.S.
T +770.970.8352, firstname.lastname@example.org
About UCB<Page: 1 2 3 4 5 6 7 Related medicine technology :1
. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease2
. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium3
. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium4
. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma5
. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG6
. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting7
. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer8
. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients9
. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe10
. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes11
. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009